We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+0.73%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$731M
AUM Growth
-$365M
Cap. Flow
-$340M
Cap. Flow %
-46.53%
Top 10 Hldgs %
45.16%
Holding
128
New
24
Increased
37
Reduced
18
Closed
39

Top Buys

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$18.7M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$11.5M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$9.99M
4
VRNT
Verint Systems
VRNT
+$9.95M
5
STOK icon
Stoke Therapeutics
STOK
+$9.42M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$31.2M
2
NVO
Novo Nordisk
NVO
+$20.9M
3
VTRS icon
Viatris
VTRS
+$13.3M
4
NVS icon
Novartis
NVS
+$9.61M
5
PTCT icon
PTC Therapeutics
PTCT
+$8.3M

Sector Composition

Rank Sector Weight
1 Healthcare 70.2%
2 Technology 11.72%
3 Industrials 2.28%
4 Consumer Discretionary 1.91%
5 Communication Services 0.61%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IFF icon
51
International Flavors & Fragrances
IFF
$20.2B
$4.35M 0.6%
+30,000
New +$4.17M
YMAB
52
DELISTED
Y-mAbs Therapeutics
YMAB
$4.34M 0.59%
+190,000
New +$4.36M
PRQR icon
53
ProQR Therapeutics
PRQR
$243M
$4.28M 0.59%
470,000
+280,000
+147% +$3.3M
NERV icon
54
Minerva Neurosciences
NERV
$185M
$4.23M 0.58%
94,002
+13,750
+17% +$688K
SIOX
55
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$4.17M 0.57%
668,541
+29,999
+5% +$228K
ITRN icon
56
Ituran Location and Control
ITRN
$1.09B
$3.91M 0.54%
+130,000
New +$4.38M
ITCI
57
CALL
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$3.89M 0.53%
300,000
– –
FISV
58
Fiserv Inc
FISV
$28.8B
$3.68M 0.5%
40,365
– –
CAMT icon
59
Camtek
CAMT
$6.18B
$3.53M 0.48%
417,459
-283,115
-40% -$2.61M
BURL icon
60
Burlington
BURL
$23.2B
$3.32M 0.45%
+19,500
New +$3.19M
SGMO
61
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$3.03M 0.41%
+281,291
New +$2.99M
WIX icon
62
WIX.com
WIX
$2.3B
$2.94M 0.4%
+20,690
New +$2.79M
WAB icon
63
Wabtec
WAB
$49.1B
$2.87M 0.39%
40,000
– –
AUTL
64
Autolus Therapeutics
AUTL
$407M
$2.86M 0.39%
177,546
-15,448
-8% -$345K
INDP icon
65
Indaptus Therapeutics
INDP
$172M
$2.69M 0.37%
+277
New +$3.49M
AAP icon
66
Advance Auto Parts
AAP
$3.35B
$2.68M 0.37%
17,400
– –
MLNX
67
DELISTED
Mellanox Technologies, Ltd.
MLNX
$2.57M 0.35%
23,217
-26,177
-53% -$3.02M
RDWR icon
68
Radware
RDWR
$1.1B
$2.53M 0.35%
102,277
+20,000
+24% +$499K
CHTR icon
69
Charter Communications
CHTR
$17.3B
$2.37M 0.32%
+6,000
New +$2.25M
ARYAU
70
DELISTED
ARYA Sciences Acquisiton Corp. Unit
ARYAU
$2.14M 0.29%
+200,000
New +$2.11M
FVRR icon
71
Fiverr
FVRR
$321M
$2.08M 0.28%
+70,000
New +$2.14M
ALNA
72
DELISTED
Allena Pharmaceuticals
ALNA
$2M 0.27%
491,193
+60,000
+14% +$328K
PRVL
73
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
$1.73M 0.24%
+130,930
New +$1.91M
MGIC
74
DELISTED
Magic Software Enterprises
MGIC
$1.66M 0.23%
185,288
+146,504
+378% +$1.31M
ORTX
75
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$1.5M 0.21%
10,743
-9,036
-46% -$1.59M
1 2
3
4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q2 2019 Portfolio in Review

As of Q2 2019, Sphera Funds Management held 128 positions worth $731M, down 33% from $1.1B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Sphera Funds Management withdrew a net $340M in Q2 2019, closing 39 positions and reducing 18 holdings. Its most notable exit was Gilead Sciences, an estimated $31.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 70% of assets, up from 55% a quarter earlier, followed by Technology and Industrials.

Against the trend, Sphera Funds Management opened a new position in Regeneron Pharmaceuticals worth $9.39M.

  • Sphera Funds Management's largest Q2 2019 buy was Regeneron Pharmaceuticals: 30,000 shares worth $9.39M.
  • Sphera Funds Management added most to Johnson & Johnson in Q2 2019, an estimated $18.7M increase.
  • Sphera Funds Management's biggest Q2 2019 reduction was Viatris, cutting an estimated $13.3M.
  • Sphera Funds Management fully exited Gilead Sciences in Q2 2019, selling an estimated $31.2M.
  • Sphera Funds Management's ten largest holdings make up 45% of its $731M portfolio in Q2 2019.
  • Sphera Funds Management opened 24 new positions and closed 39 in Q2 2019.
  • Sphera Funds Management's portfolio value fell 33% quarter-over-quarter to $731M.

Based on Sphera Funds Management's 13F filing for Q2 2019, filed 14 Aug 2019.